Alnylam Pharmaceuticals, Inc. (ALNY)

Nasdaq · Healthcare · Biotechnology
$143.82-2.71%As of 2026-11-22 · USD
Last session low $143.40Last session high $151.41
52-week low $143.4052-week high $479.79
Market cap
$19.26B
Sector
Healthcare
P/E (TTM)
7.3x

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)27.8In the oversold range (below 30)
MACD (12, 26, 9)-17.96Above its signal line (-18.51); histogram 0.54
Bollinger %B (20, 2)26%Inside the bands (116.11 to 220.70)
SMA 20168.40Price is 14.6% below
SMA 50208.86Price is 31.1% below
SMA 200270.74Price is 46.9% below
ATR (20)6.72% of priceAverage true range per day
52-week position0%At the bottom of the 143.40 to 479.79 range

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Latest fiscal yearEnded 2025-12-31: revenue of $3.71B and an operating margin of 13.5%.

More in Biotechnology